U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H42N2O5S
Molecular Weight 506.6999
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of IXABEPILONE

SMILES

C[C@@]1([H])CCC[C@]2(C)[C@]([H])(C[C@@]([H])(/C(=C(\[H])/c3csc(C)n3)/C)N=C(C[C@@]([H])(C(C)(C)C(=O)[C@]([H])(C)[C@@]1([H])O)O)O)O2

InChI

InChIKey=FABUFPQFXZVHFB-PVYNADRNSA-N
InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/mtm/ixabepilone.html | http://www.wikidoc.org/index.php/Ixabepilone | http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_report/2010/01/WC500062429.pdf

Ixabepilone is an antineoplastic agent, epothilone and mitotic inhibitor that is FDA approved for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Ixabepilone binds directly to beta-tubulin subunits on microtubules, leading to suppression of microtubule dynamics. Ixabepilone suppresses the dynamic instability of alpha-beta-II and alpha-beta-III microtubules. The most common adverse reactions (≥20%) are peripheral sensory neuropathy, fatigue/asthenia, myalgia/arthralgia, alopecia, nausea, vomiting, stomatitis/mucositis, diarrhea, and musculoskeletal pain. Inhibitors of CYP3A4 may increase plasma concentrations of ixabepilone.

Originator

Curator's Comment:: # Bristol-Myers Squibb Company

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
IXEMPRA KIT

Approved Use

IXEMPRA is indicated as monotherapy or in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated.

Launch Date

1.19249279E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
252 ng/mL
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2143 ng × h/mL
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
52 h
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
28%
40 mg/m² single, intravenous
dose: 40 mg/m²
route of administration: Intravenous
experiment type: SINGLE
co-administered:
IXABEPILONE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Disc. AE: Neuropathic pain...
Other AEs: Anorexia, Stomatitis...
AEs leading to
discontinuation/dose reduction:
Neuropathic pain (grade 3, 1 patient)
Other AEs:
Anorexia (grade 3, 1 patient)
Stomatitis (grade 3, 1 patient)
Neutropenia (grade 4, 1 patient)
Fever (grade 3, 1 patient)
Dehydration (grade 3, 1 patient)
Nausea (grade 3, 1 patient)
Vomiting (grade 3, 1 patient)
Dizziness (grade 3, 1 patient)
Sensory neuropathy (grade 3, 1 patient)
Myalgia (grade 3, 1 patient)
Alopecia (grade 2, 2 patients)
Bilirubin increased (grade 2, 1 patient)
Sources:
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
DLT: Neutropenia, Fatigue...
Dose limiting toxicities:
Neutropenia (grade 4, 2 patients)
Fatigue (grade 3, 2 patients)
Sources:
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
Other AEs: Fatigue, Anorexia...
Other AEs:
Fatigue (grade 3, 4 patients)
Anorexia (grade 3, 1 patient)
Mucositis (grade 3, 1 patient)
Neutropenia (grade 3, 13 patients)
Sources:
8 mg/m2 1 times / day multiple, intravenous
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 3
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 3
Sources:
DLT: Neutropenia...
Dose limiting toxicities:
Neutropenia (grade 4, 3 patients)
Sources:
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
DLT: Low platelets, Arthralgia...
Dose limiting toxicities:
Low platelets (grade 3, 1 patient)
Arthralgia (grade 3, 1 patient)
Sources:
7 mg/m2 1 times / day multiple, intravenous
Dose: 7 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 7 mg/m2, 1 times / day
Sources:
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
DLT: Febrile neutropenia...
Dose limiting toxicities:
Febrile neutropenia (grade 3, 2 patients)
Sources:
50 mg 3 times / day multiple, oral
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 56 years (range: 27–60 years)
n = 6
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 56 years (range: 27–60 years)
Sex: M+F
Population Size: 6
Sources:
DLT: Neutropenic sepsis...
Dose limiting toxicities:
Neutropenic sepsis (grade 4, 1 patient)
Sources:
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
DLT: Febrile neutropenia...
Other AEs: Mucosal inflammation...
Dose limiting toxicities:
Febrile neutropenia (grade 4, 1 patient)
Other AEs:
Mucosal inflammation (grade 3-4, 2 patients)
Sources:
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
Other AEs: Myalgia, Fatigue...
Other AEs:
Myalgia (grade 1, 1 patient)
Fatigue (grade 1, 1 patient)
Sources:
40 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 40 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(1000 mg/m2 twice daily for 2 weeks followed by 1 week rest)
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
Other AEs: Neutropenia...
AEs

AEs

AESignificanceDosePopulation
Bilirubin increased grade 2, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Alopecia grade 2, 2 patients
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Anorexia grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Dehydration grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Dizziness grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Fever grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Myalgia grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Nausea grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Sensory neuropathy grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Stomatitis grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Vomiting grade 3, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Neuropathic pain grade 3, 1 patient
Disc. AE
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Neutropenia grade 4, 1 patient
8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 6
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 6
Sources:
Fatigue grade 3, 2 patients
DLT
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
Neutropenia grade 4, 2 patients
DLT
10 mg/m2 1 times / day multiple, intravenous
Dose: 10 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 10 mg/m2, 1 times / day
Sources:
unhealthy, 10 years (range: 2 - 18 years)
n = 3
Health Status: unhealthy
Condition: Refractory Solid Tumors
Age Group: 10 years (range: 2 - 18 years)
Sex: M+F
Population Size: 3
Sources:
Anorexia grade 3, 1 patient
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
Mucositis grade 3, 1 patient
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
Neutropenia grade 3, 13 patients
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
Fatigue grade 3, 4 patients
6 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 16
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 16
Sources:
Neutropenia grade 4, 3 patients
DLT
8 mg/m2 1 times / day multiple, intravenous
Dose: 8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 8 mg/m2, 1 times / day
Sources:
unhealthy, 18-80 years
n = 3
Health Status: unhealthy
Age Group: 18-80 years
Population Size: 3
Sources:
Arthralgia grade 3, 1 patient
DLT
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
Low platelets grade 3, 1 patient
DLT
6.8 mg/m2 1 times / day multiple, intravenous
MTD
Dose: 6.8 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 6.8 mg/m2, 1 times / day
Sources:
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
Febrile neutropenia grade 3, 2 patients
DLT
7 mg/m2 1 times / day multiple, intravenous
Dose: 7 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 7 mg/m2, 1 times / day
Sources:
unhealthy, 54 years (range: 22–75 years)
n = 3
Health Status: unhealthy
Condition: recurrent high-grade gliomas
Age Group: 54 years (range: 22–75 years)
Sex: M+F
Population Size: 3
Sources:
Neutropenic sepsis grade 4, 1 patient
DLT
50 mg 3 times / day multiple, oral
Dose: 50 mg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg, 3 times / day
Sources:
unhealthy, 56 years (range: 27–60 years)
n = 6
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 56 years (range: 27–60 years)
Sex: M+F
Population Size: 6
Sources:
Mucosal inflammation grade 3-4, 2 patients
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
Febrile neutropenia grade 4, 1 patient
DLT
40 mg 3 times / day multiple, oral
MTD
Dose: 40 mg, 3 times / day
Route: oral
Route: multiple
Dose: 40 mg, 3 times / day
Sources:
unhealthy, 69 years (range: 39–75 years)
n = 9
Health Status: unhealthy
Condition: refractory advanced cancers
Age Group: 69 years (range: 39–75 years)
Sex: M+F
Population Size: 9
Sources:
Fatigue grade 1, 1 patient
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
Myalgia grade 1, 1 patient
100 mg/m2 single, intravenous
Overdose
Dose: 100 mg/m2
Route: intravenous
Route: single
Dose: 100 mg/m2
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Sex: F
Population Size: 1
Sources:
Neutropenia grade 5
40 mg/m2 1 times / 3 weeks multiple, intravenous
Recommended
Dose: 40 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 40 mg/m2, 1 times / 3 weeks
Co-administed with::
capecitabine(1000 mg/m2 twice daily for 2 weeks followed by 1 week rest)
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: F
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
inconclusive
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no [IC50 >30 uM]
unlikely
Comment: ixabepilone is not likely to be an inhibitor of CYP450 enzymes or cause drug-drug interactions via CYP450 inhibition with coadministered drugs that are metabolized by CYP450 enzymes in-vivo
Page: 31.0
no
no
no
no
yes [IC50 15 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
inconclusive
major
yes (co-administration study)
Comment: coadministration with ketoconazole increased AUC by 1.8-fold but no difference in Cmax values; CYP3A4 inhibitors should be used with caution in patients taking ixabepilone.
Page: 30, 34
no
no
no
no
no
no
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
2008 Feb
Patents

Sample Use Guides

40 mg/m2 infused over 3 hours every 3 weeks
Route of Administration: Intravenous
Hepatocellular carcinoma cell lines were sensitive to ixabepilone, with the IC50 range 2.5–44.1 nmol/l.
Name Type Language
IXABEPILONE
DASH   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
IXABEPILONE [MART.]
Common Name English
IXABEPILONE [MI]
Common Name English
1S,3S,7S,10R,11S,12S,16R)-7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-((1E)-1-METHYL-2-(2-METHYLTHIAZOL-4-YL)ETHENYL)-17-OXA-4-AZABICYCLO(14.1.0)HEPTADECANE-5,9-DIONE
Common Name English
IXABEPILONE [INN]
Common Name English
AZAEPOTHILONE B
Common Name English
NSC-747973
Code English
BMS-247550
Code English
IXABEPILONE [USP-RS]
Common Name English
(1R,5S,6S,7R,10S,14S,16S)-6,10-DIHYDROXY-1,5,7,9,9-PENTAMETHYL-14-((E)-1-(2-METHYL-1,3-THIAZOL-4-YL)PROP-1-EN-2-YL)-17-OXA-13-AZABICYCLO(14.1.0)HEPTADECANE-8,12-DIONE
Systematic Name English
IXABEPILONE [USAN]
Common Name English
IXABEPILONE [ORANGE BOOK]
Common Name English
IXABEPILONE [HSDB]
Common Name English
IXABEPILONE [VANDF]
Common Name English
BMS-247550-01
Code English
IXEMPRA KIT
Brand Name English
IXABEPILONE [JAN]
Common Name English
IXEMPRA
Brand Name English
IXABEPILONE [USP MONOGRAPH]
Common Name English
BMS 247550-01
Code English
17-OXA-4-AZABICYCLO(14.1.0)HEPTADECANE-5,9-DIONE, 7,11-DIHYDROXY-8,8,10,12,16-PENTAMETHYL-3-((1E)-1-METHYL-2-(2-METHYL-4-THIAZOLYL)ETHENYL)-, (1S,3S,7S,10R,11S,12S,16R)-
Common Name English
IXABEPILONE [WHO-DD]
Common Name English
Classification Tree Code System Code
LIVERTOX 528
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
NCI_THESAURUS C2584
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
NDF-RT N0000175085
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
WHO-VATC QL01DC04
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
NDF-RT N0000175592
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
WHO-ATC L01DC04
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
Code System Code Type Description
RXCUI
337523
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY RxNorm
DRUG BANK
DB04845
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
EVMPD
SUB33513
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
FDA UNII
K27005NP0A
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
USP_CATALOG
1354400
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY USP-RS
PUBCHEM
6445540
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
CAS
219989-84-1
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
IUPHAR
6824
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201752
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
DRUG CENTRAL
1517
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
MESH
C430592
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
MERCK INDEX
M6567
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY Merck Index
HSDB
7738
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
NCI_THESAURUS
C37452
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
WIKIPEDIA
IXABEPILONE
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY
INN
8390
Created by admin on Fri Jun 25 22:05:26 UTC 2021 , Edited by admin on Fri Jun 25 22:05:26 UTC 2021
PRIMARY